DK1663161T3 - Estradiol-progesteron-formulering med langsom afgivelse - Google Patents
Estradiol-progesteron-formulering med langsom afgivelse Download PDFInfo
- Publication number
- DK1663161T3 DK1663161T3 DK04736545.7T DK04736545T DK1663161T3 DK 1663161 T3 DK1663161 T3 DK 1663161T3 DK 04736545 T DK04736545 T DK 04736545T DK 1663161 T3 DK1663161 T3 DK 1663161T3
- Authority
- DK
- Denmark
- Prior art keywords
- estradiol
- formulation
- microspheres
- progesterone
- approx
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
1. Formulering, som er egnet til administration til et hunpattedyr og omfatter ca. 5 til ca. 15 mg 17-p-estradiol blandet med cholesterol i et ca. 1:1 molært forhold og ca. 200 til ca. 500 mg progesteron; hvor vægtforholdet mellem 17-p-estradiol og progesteron er ca. 1:40; 17-p-estradiol består af en hemikrystallinsk form, som erca. 50-60% amorf og ca. 40-50% krystallinsk; og EDR af formuleringen er ca. 20% eller mindre.
2. Formulering ifølge krav 1, hvor 17-p-estradiol består af en hemikrystallinsk form, som er ca. 55% amorf og ca. 45% krystallinsk.
3. Formulering ifølge krav 1 eller krav 2, hvor EDR er ca. 6% eller mindre.
4. Formulering ifølge et hvilket som helst af kravene 1 til 3, hvor estradiol/cholesterol-blandingen og progesteron er formuleret som mikrosfærer med en diameter på ca. 35 til ca. 75 μιτι.
5. Formulering, som omfatter en præventionseffektiv og hormonerstatningseffektiv mængde 17-p-estradiol og progesteron i et vægtforhold på ca. 1:40, og hvor 17-p-estradiol er sammensat i separate partikler i blanding med cholesterol.
6. Formulering ifølge krav 5, hvor vægtforholdet 17-p-estradiol:progesteron er 9:400.
7. Formulering ifølge krav 5, hvor 17-p-estradiol og cholesterol er sammensat i et 1:1 molært forhold til mikrosfærer, og progesteron er separat sammensat til separate mikrosfærer.
8. Formulering ifølge krav 5, hvor mikrosfærerne har en diameter på mellem ca. 25 μηι og ca. 105 prn.
9. Formulering ifølge et hvilket som helst af kravene 1 til 8, som er egnet til parenteral administration.
10. Formulering ifølge krav 9, som er egnet til intramuskulær injektion.
11. Formulering ifølge et hvilket som helst af kravene 1 til 10 til anvendelse til prævention i et hunpattedyr i de reproduktive år.
12. Formulering ifølge et hvilket som helst af kravene 1 til 10 til anvendelse til hormonerstatningsterapi i et hunpattedyr i de første fem år af menopausen.
13. Kit, som omfatter (1) en steril pakning omfattende en enhedsdosis afen formulering ifølge krav 1 i form af mikrosfærer i steril pulverform og (2) en steril pakning omfattende en vandig bærer til suspendering af mikrosfærerne til parenteral administration.
14. Kit ifølge krav 13, som desuden omfatter et middel til parenteral administration af formuleringen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47793903P | 2003-06-13 | 2003-06-13 | |
| PCT/IB2004/001930 WO2004110408A2 (en) | 2003-06-13 | 2004-06-10 | Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1663161T3 true DK1663161T3 (da) | 2015-04-27 |
Family
ID=33551788
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07008938.8T DK1844765T3 (da) | 2003-06-13 | 2004-06-10 | Estradiol-progesteron-formulering med langsom afgivelse |
| DK04736545.7T DK1663161T3 (da) | 2003-06-13 | 2004-06-10 | Estradiol-progesteron-formulering med langsom afgivelse |
| DK07008942T DK1820494T3 (da) | 2003-06-13 | 2004-06-10 | Mikropartikler bestående af estradiol og cholesterol |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07008938.8T DK1844765T3 (da) | 2003-06-13 | 2004-06-10 | Estradiol-progesteron-formulering med langsom afgivelse |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07008942T DK1820494T3 (da) | 2003-06-13 | 2004-06-10 | Mikropartikler bestående af estradiol og cholesterol |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7589082B2 (da) |
| EP (3) | EP1844765B1 (da) |
| JP (2) | JP4956185B2 (da) |
| CN (2) | CN101816662B (da) |
| AT (1) | ATE454885T1 (da) |
| AU (1) | AU2004246870B2 (da) |
| BR (1) | BRPI0411335A (da) |
| CA (2) | CA2849228C (da) |
| CY (1) | CY1109967T1 (da) |
| DE (1) | DE602004025156D1 (da) |
| DK (3) | DK1844765T3 (da) |
| EA (3) | EA026709B1 (da) |
| ES (3) | ES2537551T3 (da) |
| HU (1) | HUE025147T2 (da) |
| IL (2) | IL172466A (da) |
| MX (1) | MX2008014654A (da) |
| NO (1) | NO341540B1 (da) |
| OA (1) | OA13307A (da) |
| PL (3) | PL1663161T3 (da) |
| PT (3) | PT1844765E (da) |
| SI (3) | SI1844765T1 (da) |
| TW (1) | TWI336623B (da) |
| WO (1) | WO2004110408A2 (da) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1844765T1 (sl) | 2003-06-13 | 2015-05-29 | Skendi Finance, Ltd. | Formulacija estradiola in progesterona s počasnim sproščanjem |
| BRPI0822165A2 (pt) * | 2008-04-14 | 2015-06-16 | Posi Visionary Solutions Llp | Método para manter concentrações plasmáticas sustentadas de progesterona em seres humanos, composição farmacêutica, uso de uma composição farmecêutica e suspensão aquosa injetável. |
| UY33103A (es) * | 2009-12-15 | 2011-07-29 | Techsphere S A De C V | Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico |
| EP2701744A4 (en) * | 2011-03-23 | 2014-08-20 | Pop Test Cortisol Llc | COMBINATION THERAPY |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| LT2782584T (lt) | 2011-11-23 | 2021-09-10 | Therapeuticsmd, Inc. | Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| CA2951284A1 (en) | 2014-07-29 | 2016-02-04 | Therapeuticsmd, Inc. | Transdermal cream |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| ITUB20153652A1 (it) * | 2015-09-16 | 2017-03-16 | Fatro Spa | Microsfere contenenti lattoni macrociclici antielminitici |
| JP2019513709A (ja) | 2016-04-01 | 2019-05-30 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | ステロイドホルモン薬学的組成物 |
| RU2018133921A (ru) * | 2016-04-01 | 2020-05-12 | Терапьютиксмд, Инк. | Фармацевтическая композиция стероидных гормонов |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| EP3272732B1 (de) | 2016-07-19 | 2019-09-18 | Evonik Degussa GmbH | Verfahren zur alkoxycarbonylierung ethylenisch ungesättigter verbindungen mit monophosphinliganden |
| CN119792305A (zh) * | 2018-11-29 | 2025-04-11 | 因斯格纳公司 | 作为不育剂的苯甲酸雌二醇 |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| EP3954364A1 (en) * | 2020-08-14 | 2022-02-16 | Chemo Research, S.L. | New modified release oral contraceptive composition |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3800038A (en) * | 1972-04-21 | 1974-03-26 | Biolog Concepts Inc | Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier |
| GB1367608A (en) * | 1973-03-09 | 1974-09-18 | Biolog Concepts Inc | Oral pharmaceutical dosage form |
| US4218255A (en) * | 1976-08-30 | 1980-08-19 | University Of Dayton | Porous ceramic carriers for controlled release of proteins, polypeptide hormones, and other substances within human and/or other mamillian species and method |
| US4180560A (en) * | 1976-10-26 | 1979-12-25 | Syntex Corporation | Inert core implant pellet |
| JPS5799562A (en) | 1980-12-12 | 1982-06-21 | Nippon Shinyaku Co Ltd | Preparation of microcrystal |
| US5023092A (en) | 1988-06-16 | 1991-06-11 | Ici Americas Inc. | Mannitol having gamma sorbitol polymorph |
| IT1230566B (it) | 1988-10-17 | 1991-10-28 | Vectorpharma Int | Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione |
| US5252334A (en) | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
| FR2663223B1 (fr) * | 1990-06-14 | 1994-12-02 | Af Aplicaciones Far Lab | Forme galenique parenterale. |
| FR2663224B1 (fr) | 1990-06-14 | 1995-01-20 | Applicationes Farmaceuticas Sa | Forme galenique parenterale. |
| IE71203B1 (en) | 1990-12-13 | 1997-02-12 | Akzo Nv | Low estrogen oral contraceptives |
| IE62665B1 (en) | 1990-12-17 | 1995-02-22 | Akzo Nv | Contraceptive regimen |
| SE9101090D0 (sv) * | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
| US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| DE4130173A1 (de) | 1991-09-11 | 1993-03-18 | Bayer Ag | Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters |
| SE9301171D0 (sv) | 1993-04-07 | 1993-04-07 | Ab Astra | Pharmaceutical composition containing lipophilic drugs |
| TW360548B (en) | 1993-04-08 | 1999-06-11 | Powderject Res Ltd | Products for therapeutic use |
| FR2747042B1 (fr) | 1996-04-05 | 1998-06-05 | Besins Iscovesco Lab | Medicament a base de progesterone et d'oestradiol |
| US5762956A (en) | 1996-04-24 | 1998-06-09 | Rutgers, The State University Of New Jersey | Transdermal contraceptive delivery system and process |
| EP0888790A1 (en) | 1997-07-04 | 1999-01-07 | PowderJect Research Limited | Drug particle delivery device |
| US6287693B1 (en) | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
| US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
| ATE307591T1 (de) * | 2000-12-14 | 2005-11-15 | Ortho Mcneil Pharm Inc | Zubereitungen enthaltend ein steroidhormon und ein stabilisierungsmittel in nicht-kristalliner form |
| US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
| SI1844765T1 (sl) | 2003-06-13 | 2015-05-29 | Skendi Finance, Ltd. | Formulacija estradiola in progesterona s počasnim sproščanjem |
-
2004
- 2004-06-10 SI SI200432238T patent/SI1844765T1/sl unknown
- 2004-06-10 PT PT70089388T patent/PT1844765E/pt unknown
- 2004-06-10 PT PT47365457T patent/PT1663161E/pt unknown
- 2004-06-10 ES ES04736545.7T patent/ES2537551T3/es not_active Expired - Lifetime
- 2004-06-10 SI SI200431384T patent/SI1820494T1/sl unknown
- 2004-06-10 EA EA201201221A patent/EA026709B1/ru not_active IP Right Cessation
- 2004-06-10 EA EA200600029A patent/EA012783B1/ru not_active IP Right Cessation
- 2004-06-10 DK DK07008938.8T patent/DK1844765T3/da active
- 2004-06-10 SI SI200432235T patent/SI1663161T1/sl unknown
- 2004-06-10 CA CA2849228A patent/CA2849228C/en not_active Expired - Fee Related
- 2004-06-10 DE DE200460025156 patent/DE602004025156D1/de not_active Expired - Lifetime
- 2004-06-10 HU HUE04736545A patent/HUE025147T2/hu unknown
- 2004-06-10 PL PL04736545T patent/PL1663161T3/pl unknown
- 2004-06-10 AU AU2004246870A patent/AU2004246870B2/en not_active Ceased
- 2004-06-10 EP EP20070008938 patent/EP1844765B1/en not_active Expired - Lifetime
- 2004-06-10 PL PL07008942T patent/PL1820494T3/pl unknown
- 2004-06-10 PT PT07008942T patent/PT1820494E/pt unknown
- 2004-06-10 ES ES07008938.8T patent/ES2537563T3/es not_active Expired - Lifetime
- 2004-06-10 ES ES07008942T patent/ES2340422T3/es not_active Expired - Lifetime
- 2004-06-10 DK DK04736545.7T patent/DK1663161T3/da active
- 2004-06-10 BR BRPI0411335 patent/BRPI0411335A/pt not_active Application Discontinuation
- 2004-06-10 CA CA2528545A patent/CA2528545C/en not_active Expired - Fee Related
- 2004-06-10 CN CN200910258692.9A patent/CN101816662B/zh not_active Expired - Fee Related
- 2004-06-10 JP JP2006516535A patent/JP4956185B2/ja not_active Expired - Fee Related
- 2004-06-10 AT AT07008942T patent/ATE454885T1/de active
- 2004-06-10 CN CN200480023175A patent/CN100594907C/zh not_active Expired - Fee Related
- 2004-06-10 DK DK07008942T patent/DK1820494T3/da active
- 2004-06-10 WO PCT/IB2004/001930 patent/WO2004110408A2/en not_active Ceased
- 2004-06-10 EA EA200900451A patent/EA018356B1/ru not_active IP Right Cessation
- 2004-06-10 OA OA1200500357A patent/OA13307A/en unknown
- 2004-06-10 EP EP20070008942 patent/EP1820494B1/en not_active Expired - Lifetime
- 2004-06-10 PL PL07008938T patent/PL1844765T3/pl unknown
- 2004-06-10 EP EP20040736545 patent/EP1663161B1/en not_active Expired - Lifetime
- 2004-06-10 US US10/864,470 patent/US7589082B2/en not_active Expired - Fee Related
- 2004-06-10 MX MX2008014654A patent/MX2008014654A/es active IP Right Grant
- 2004-06-14 TW TW93117058A patent/TWI336623B/zh not_active IP Right Cessation
-
2005
- 2005-12-08 IL IL172466A patent/IL172466A/en active IP Right Grant
-
2006
- 2006-01-13 NO NO20060200A patent/NO341540B1/no not_active IP Right Cessation
-
2008
- 2008-12-02 US US12/326,316 patent/US8163722B2/en not_active Expired - Fee Related
-
2010
- 2010-04-12 CY CY101100328T patent/CY1109967T1/el unknown
-
2011
- 2011-01-25 IL IL210851A patent/IL210851A/en active IP Right Grant
- 2011-04-06 JP JP2011084716A patent/JP2011157386A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8163722B2 (en) | Pharmaceutical formulation for contraception and hormone-replacement therapy | |
| CN1211087C (zh) | 用于适应需要的女性生育节制的竞争性黄体酮拮抗剂 | |
| HK1106717B (en) | Microparticles consisting of estradiol and cholesterol | |
| HK1109586B (en) | Slow release estradiol-progesterone formulation | |
| MXPA05013507A (es) | Formulacion de liberacion lenta de estradiol-progesterona paraanticoncepcion y terapia de reemplazo hormonal | |
| HK1097735B (en) | Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol | |
| HK1147426B (en) | Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol | |
| Segal | Contraceptives for the Twenty-First Century |